Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) and Pioglitazone (PIO) Over 52 Weeks

被引：0
|
作者：
Forst, Thomas
Guthrie, Robert
Goldenberg, Ronald
Yee, Jacqueline
Vijapurkar, Ujjwala
Meininger, Gary
Stein, Peter
机构：
来源：
DIABETES | 2013年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1098-P
引用
收藏
页码：A284 / A284
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Canagliflozin (CANA) Monotherapy in Subjects With Type 2 Diabetes Mellitus (T2DM) Over 52 Weeks
    Stenloef, Kaj
    Cefalu, William T.
    Kim, Kyoung-Ah
    Jodar, Esteban
    Alba, Maria
    Edwards, Robert
    Tong, Cindy
    Canovatchel, William
    Meininger, Gary
    [J]. DIABETES, 2013, 62 : A303 - A303
  • [2] Canagliflozin (CANA) Compared With Sitagliptin (SITA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) Over 52 Weeks
    Lavalle Gonzalez, Fernando J.
    Januszewicz, Andrzej
    Davidson, Jaime
    Qiu, Rose
    Tong, Cindy
    Meininger, Gary
    [J]. DIABETES, 2013, 62 : A61 - A61
  • [3] Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) Over 52 Weeks
    Yale, Jean-Francois
    Bakris, George
    Cariou, Bertrand
    Iglesias, Javier Nieto
    Wajs, Ewa
    Figueroa, Katherine
    Jiang, Joel
    Usiskin, Keith
    Meininger, Gary
    [J]. DIABETES, 2013, 62 : A277 - A278
  • [4] Long-term Efficacy and Safety of Canagliflozin (CANA) in Older Patients with Type 2 Diabetes Mellitus (T2DM) Over 104 Weeks
    Bode, Bruce
    Stenlof, Kaj
    Harris, Stewart
    Sullivan, Daniel
    Fung, Albert
    Usiskin, Keith
    [J]. DIABETES, 2014, 63 : A71 - A71
  • [5] Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
    Forst, T.
    Guthrie, R.
    Goldenberg, R.
    Yee, J.
    Vijapurar, U.
    Meiningers, G.
    Stein, P.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (05): : 467 - 477
  • [6] Efficacy and Safety of Canagliflozin (CANA) in Japanese Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Diet and Exercise over 24 Weeks
    Inagaki, Nobuya
    Kondo, Kazuoki
    Yoshinari, Toru
    Maruyama, Nobuko
    Takahashi, Nahoko
    Susuta, Yutaka
    Kuki, Hideki
    [J]. DIABETES, 2014, 63 : A266 - A266
  • [7] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Nyirjesy, Paul
    Sobel, Jack
    Fung, Albert
    Gassmann-Mayer, Cristiana
    Ways, Kirk
    Usiskin, Keith
    [J]. DIABETES, 2013, 62 : A276 - A276
  • [8] Efficacy and safety of canagliflozin in subjects with type 2 diabetes mellitus inadequately controlled with metformin plus sulphonylurea over 52 weeks
    Vercruysse, F.
    Charpentier, G.
    Wilding, J.
    Hollander, P.
    Gonzalez Galvez, G.
    Mathieu, C.
    Usiskin, K.
    Vijapurkar, U.
    Black, S.
    Canovatchel, W.
    Meininger, G.
    [J]. DIABETOLOGIA, 2013, 56 : S373 - S373
  • [9] Urinary Tract Infection (UTI) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Nicolle, Lindsay E.
    Capuano, George
    Fung, Albert
    Usiskin, Keith
    [J]. DIABETES, 2013, 62 : A296 - A296
  • [10] Lower Blood Pressure (BP) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Weir, Matthew R.
    Januszewicz, Andrzej
    Gilbert, Richard
    Gonzalez, Fernando Lavalle
    Meininger, Gary
    [J]. DIABETES, 2013, 62 : A278 - A278
12345